- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04676802
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
Pain Relief After Trapeziectomy Without Opioids: Ibuprofen & Acetaminophen Versus Oxycodone
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Deborah Kenney, MS OTR
- Phone Number: 6507217644
- Email: dkenney@stanford.edu
Study Locations
-
-
California
-
Redwood City, California, United States, 94063
- Recruiting
- Stanford Health Care
-
Contact:
- Deborah Kenney, MS OTR
- Phone Number: 650-721-7644
- Email: dkenney@stanford.edu
-
Principal Investigator:
- Amy Ladd, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Undergoing trapeziectomy for thumb osteoarthritis
English proficient,
Exclusion Criteria:
- Pregnancy
Current use of opioids
Concurrent surgeries (ex. trapeziectomy combined with carpal tunnel release)
Inability to complete study forms (education, cognitive ability, mental status, medical status)
Allergy or intolerance to Ibuprofen, Acetaminophen and/or Oxycodone
Liver or kidney dysfunction, abnormal liver enzymes restricting use of acetaminophen or ibuprofen
History of chronic heart failure, upper gastrointestinal bleeding or coagulopathy
History of complex regional pain syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NSAIDS
Following surgery will receive NSAID capsules following surgery.
Will take online and phone surveys.
|
1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
|
Experimental: Opioids
Following surgery will receive opioid capsules following surgery.
Will take online and phone surveys.
|
1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of medication consumption and overall amount
Time Frame: Every day from the first day after surgery to 30 days post-op.
|
The number of capsules consumed in the last 24 hours.
Consumption rate and overall consumption will be compared between groups to assess efficacy and inform further statistical analyses.
|
Every day from the first day after surgery to 30 days post-op.
|
Change of worst daily pain score measured over time
Time Frame: Every day from the first day after surgery to 30 days post-op.
|
Numerical score describing surgical pain at its worst in the last 24 hours, between 1 and 10, 1 being no pain, 10 being the worst possible pain.
|
Every day from the first day after surgery to 30 days post-op.
|
Change of least daily pain score measured over time
Time Frame: Every day from the first day after surgery to 30 days post-op.
|
Numerical score describing surgical pain at its least in the last 24 hours, between 1 and 10, 1 being no pain, 10 being the worst possible pain.
|
Every day from the first day after surgery to 30 days post-op.
|
Change of average daily pain score measured over time
Time Frame: Every day from the first day after surgery to 30 days post-op.
|
Numerical score describing average surgical pain in the last 24 hours, between 1 and 10, 1 being no pain, 10 being the worst possible pain.
|
Every day from the first day after surgery to 30 days post-op.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quick DASH scores over time
Time Frame: Baseline, Post-operative weeks 1, 3, 5, and 8
|
Quick Disabilities of the Arm, Shoulder, and Hand (qDASH) is a responsive measure to patient-reported functional change in the hand and upper extremity patient population, ranging from 0 to 100.
Lower scores signify limited function and increased pain.
|
Baseline, Post-operative weeks 1, 3, 5, and 8
|
Change in PROMIS-PI scores over time
Time Frame: Baseline, Post-operative weeks 1, 3, 5, and 8
|
PROMIS-PI scores (Patient-Reported Outcomes Measurement Information System - Pain Interference) are effective measures of the change in perceived pain, supporting intervention related studies assessing power analyses for comparative research. We use the Pain Interference - Short Form version 6b, which consists of 6 questions regarding how much the pain experienced in the last 7 days interfered with everyday aspects of life (i.e. enjoyment, ability to concentrate, day to day activities, recreational activities, doing tasks away from home, and socializing with others). The answers to all questions are ordinals ranging from 1 (not interfered at all) to 5 (interfered very much). |
Baseline, Post-operative weeks 1, 3, 5, and 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Amy Ladd, MD, Stanford Orthopaedic Surgery
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 58972
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Postoperative
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
Clinical Trials on NSAID capsules
-
Aalborg UniversityCompleted
-
Regional Hospital HolstebroCompleted
-
St. Louis UniversityWithdrawn
-
Yonsei UniversityCompletedMyofascial Pain Syndrome of the Upper TrapeziusKorea, Republic of
-
Kayseri City HospitalCompleted
-
LEO PharmaCompleted
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting